since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.
![Vaxart logo](/files/LOGO/72444-VXRT.png)
Company profile
Ticker
VXRT
Exchange
Website
CEO
Andrei Floroiu
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI /DE/, NABI BIOPHARMACEUTICALS, NORTH AMERICAN BIOLOGICALS INC
SEC CIK
Corporate docs
Subsidiaries
Vaxart Biosciences, Inc. • Biota Holdings • Biota Scientific Management Pty, Ltd. ...
IRS number
591212264
VXRT stock data
Latest filings (excl ownership)
8-K
Vaxart Provides Business Update
17 Jun 24
424B5
Prospectus supplement for primary offering
17 Jun 24
8-K
Vaxart Announces $40 Million Underwritten Offering of Common Stock
14 Jun 24
8-K
Entry into a Material Definitive Agreement
13 Jun 24
8-K
Departure of Directors or Certain Officers
13 Jun 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
13 May 24
8-K
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
30 Apr 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
Transcripts
VXRT
Earnings call transcript
2024 Q1
13 May 24
VXRT
Earnings call transcript
2023 Q3
2 Nov 23
VXRT
Earnings call transcript
2023 Q2
3 Aug 23
VXRT
Earnings call transcript
2023 Q2
3 Aug 23
VXRT
Earnings call transcript
2023 Q1
4 May 23
VXRT
Earnings call transcript
2022 Q4
15 Mar 23
VXRT
Earnings call transcript
2022 Q3
9 Nov 22
VXRT
Earnings call transcript
2022 Q2
9 Aug 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.74 mm | 26.74 mm | 26.74 mm | 26.74 mm | 26.74 mm | 26.74 mm |
Cash burn (monthly) | 2.67 mm | 1.81 mm | 8.12 mm | 6.87 mm | 7.06 mm | 5.60 mm |
Cash used (since last report) | 7.06 mm | 4.77 mm | 21.44 mm | 18.13 mm | 18.64 mm | 14.78 mm |
Cash remaining | 19.68 mm | 21.96 mm | 5.29 mm | 8.60 mm | 8.09 mm | 11.96 mm |
Runway (months of cash) | 7.4 | 12.1 | 0.7 | 1.3 | 1.1 | 2.1 |
Institutional ownership, Q4 2023
5.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 64 |
Opened positions | 5 |
Closed positions | 36 |
Increased positions | 12 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 5.61 bn |
Total shares | 10.51 mm |
Total puts | 0.00 |
Total calls | 69.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 7.04 mm | $4.04 bn |
Gsa Capital Partners | 488.50 k | $280.00 k |
STT State Street | 466.55 k | $267.24 mm |
MS Morgan Stanley | 370.22 k | $212.06 mm |
NTRS Northern Trust | 334.14 k | $191.39 mm |
IHT Wealth Management | 237.57 k | $136.08 mm |
Raymond James Financial Services Advisors | 195.62 k | $112.05 mm |
Charles Schwab Investment Management | 153.55 k | $87.95 mm |
Private Portfolio Partners | 103.17 k | $59.10 mm |
Dimensional Fund Advisors | 79.10 k | $45.31 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jun 24 | Phillip E Lee | Common Stock | Payment of exercise | Dispose F | No | No | 0.76 | 2,007 | 1.53 k | 239,801 |
11 Jun 24 | Watson W. Mark | Common Stock | Grant | Acquire A | No | No | 0 | 16,000 | 0.00 | 58,125 |
11 Jun 24 | Watson W. Mark | Stock Option Common Stock | Grant | Acquire A | No | No | 0.77 | 95,400 | 73.46 k | 95,400 |
11 Jun 24 | Robert A. Yedid | Common Stock | Grant | Acquire A | No | No | 0 | 16,000 | 0.00 | 34,490 |
11 Jun 24 | Robert A. Yedid | Stock Option Common Stock | Grant | Acquire A | No | No | 0.77 | 95,400 | 73.46 k | 95,400 |
11 Jun 24 | Finney Michael J. | Common Stock | Grant | Acquire A | No | No | 0 | 16,000 | 0.00 | 686,840 |
11 Jun 24 | Finney Michael J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.77 | 95,400 | 73.46 k | 95,400 |
11 Jun 24 | Heron Elaine J | Common Stock | Grant | Acquire A | No | No | 0 | 16,000 | 0.00 | 40,566 |
11 Jun 24 | Heron Elaine J | Stock Option Common Stock | Grant | Acquire A | No | No | 0.77 | 95,400 | 73.46 k | 95,400 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
19 Jun 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
18 Jun 24
Vaxart Stock Is Moving Higher After The Bell: What's Going On?
17 Jun 24
Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026
17 Jun 24
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
14 Jun 24
Press releases
Vaxart Provides Business Update
17 Jun 24
Vaxart Announces $40 Million Underwritten Offering of Common Stock
13 Jun 24
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
13 Jun 24
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
13 May 24